XtalPi Collaborated with CK Life Sciences to Develop AI-Empowered Tumour Vaccine Research and Development Platform
- The collaboration combines XtalPi's AI algorithm, molecular modeling & automated experiments to develop an AI tumor vaccine R&D platform & design capabilities of tumor vaccines to activate specific immune responses to kill tumors, accelerate the R&D process, improve the success rate & efficacy of tumor vaccines
- The platform is designed to provide a preclinical tumor vaccine candidate compound with robust immune activity. Tumor vaccines targeting various tumor neoantigens, TAA, and TSA in patients can be created for use as immunotherapy triggering the patient's immune responses
- Two therapeutic tumor vaccines are currently available i.e., sipuleucel-T for melanoma & BCG for bladder cancer along with preventive tumor vaccines against HPV & hepatitis B inf.
Ref: PRNewswire | Image: CK Life Sciences
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.